ReviewKidney international2026
The role of the vascular niche in regulating kidney tubulointerstitial fibrosis.
Review in Kidney international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Applying dendrimer nanoprobes to the diagnosis and evaluation of kidney fibrosis.Nanomedicine (London, England) · 2026Review
- From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic kidney disease (CKD) is a substantial global health problem with devastating impacts on patients' morbidity and mortality. Kidney fibrosis, specifically tubulointerstitial fibrosis, is considered the final common pathway in the progression of virtually all forms of CKD. Peritubular capillary rarefaction, which refers to a decrease in peritubular capillary density leading to hypoxic and ischemic conditions, has long been recognized as a hallmark pathologic feature of tubulointerstitial fibrosis and a pivotal biological alteration leading to CKD progression. Conversely, recent literature has challenged this paradigm by proposing that tubulointerstitial fibrosis and CKD progression are closely associated with the upregulation of proangiogenic pathways. As such, peritubular capillary rarefaction may be a consequence rather than a cause of tubulointerstitial fibrosis. Furthermore, a growing body of evidence suggests that the microenvironment of the kidney vasculature, which may be referred to as the vascular niche, is a dynamic entity that regulates vascular homeostasis, key molecular signaling pathways, and inflammation. In this review, we detail how the vascular niche may modify the course of various kidney diseases by influencing cell differentiation and the immune response. Understanding the complex interplay between the cellular and molecular components of the vascular niche may eventually lead to the identification of novel therapeutic targets to limit tubulointerstitial fibrosis and halt CKD progression. This could potentially involve modulating the secretion of angiocrine factors, regulating immune cell activity within the vascular niche, or interfering with the transformation of endothelial cells and pericytes into myofibroblasts, which are key players in kidney fibrogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.